Content about Alcon

October 3, 2013

Most contact lens wearers in the United States put their eyes at risk by cutting corners and adopting bad habits when it comes to contact lens care and hygiene practices, according to a recent global survey conducted by Wakefield Research for Alcon.

DALLAS — Most contact lens wearers in the United States put their eyes at risk by cutting corners and adopting bad habits when it comes to contact lens care and hygiene practices, according to a recent global survey conducted by Wakefield Research for Alcon.

September 10, 2013

In an effort to help highlight the role that good eye health and clear vision play in life, Alcon grouped its over-the-counter eye care products into one easy-to-shop solution — the eyeSolution.

FORT WORTH, Texas — In an effort to help highlight the role that good eye health and clear vision play in life, Alcon grouped its over-the-counter eye care products into one easy-to-shop solution — the eyeSolution. The eyeSolution portfolio includes Clear Care Solution for contact lens wearers, ICaps Eye Vitamins, Naphcon-A Eye Allergy Drops, Opti-Free, Systane and Zaditor Eye Allergy Drops.

 

 

September 10, 2013

Cirrus Healthcare Products earlier this summer launched a new licensed version of EarPlanes for Kids in conjunction with the new Disney "Planes" movie.

COLD SPRING HARBOR. N.Y. — Cirrus Healthcare Products earlier this summer launched a new licensed version of EarPlanes for Kids in conjunction with the new Disney "Planes" movie. EarPlanes are designed to be worn for air travel to reduce and prevent uncomfortable ear pressure during flight, including clogging, popping and pain.

 

July 15, 2013

Actress Jennie Garth, known for her role on "Beverly Hills 90210," on Monday partnered with Alcon to launch the Eye Saw Good campaign, an initiative that highlights the important role that good eye health and clear vision play in a person's life.

FORT WORTH, Texas — Actress Jennie Garth, known for her role on "Beverly Hills 90210," on Monday partnered with Alcon to launch the Eye Saw Good campaign, an initiative that highlights the important role that good eye health and clear vision play in a person's life. The campaign has been set up to inspire people to help provide good eye health and vision correction for children in need across the United States. The campaign is simple: see good, share good and make good happen.

April 22, 2013

The Food and Drug Administration has approved a drug made by Alcon, the drug maker said.

BASEL, Switzerland — The Food and Drug Administration has approved a drug made by Alcon, the drug maker said.

April 12, 2013

Early last week the National Advertising Division recommended that Bausch + Lomb modify or discontinue certain claims made in an advertorial context that refer to Alcon Laboratories' Opti-Free RepleniSH contact lens solution.

NEW YORK — Earlier this week the National Advertising Division recommended that Bausch + Lomb modify or discontinue certain claims made in an advertorial context that refer to Alcon Laboratories' Opti-Free RepleniSH contact lens solution.

March 21, 2013

Alcon has launched a mobile website designed to facilitate dialogue between patients and pharmacists about eye and ear treatments, the company said.

NEW YORK — Alcon has launched a mobile website designed to facilitate dialogue between patients and pharmacists about eye and ear treatments, the company said Thursday.

Alcon announced the launch of Drops101 Web Tools, which offers access to information about two of its products: Ciprodex Otic (ciprofloxacin and dexamethasone), for acute otitis externa and acute otitis media in children with tymponostomy tubes; and Moxeza ophthalmic solution (moxifloxacin hydrochloride) for bacterial conjunctivitis.

January 21, 2013

Eye care company Alcon has launched a treatment for pain and inflammation resulting from cataract surgery, the company said Monday.

NEW YORK — Eye care company Alcon has launched a treatment for pain and inflammation resulting from cataract surgery, the company said Monday.

The company said Ilevro (nepafenac) ophthalmic suspension was a nonsteroidal anti-inflammatory drug and once-daily treatment for cataract surgery patients.

June 15, 2011

Watson Pharmaceuticals has filed a regulatory approval application with the Food and Drug Administration for a generic drug for eye disease, the company said Tuesday.

PARSIPPANY, N.J. — Watson Pharmaceuticals has filed a regulatory approval application with the Food and Drug Administration for a generic drug for eye disease, the company said Tuesday.

Watson is seeking approval for olopatadine hydrochloride ophthalmic solution in the 0.2% strength. The drug, used to treat itching in the eye resulting from allergic conjunctivitis, is a generic version of Alcon’s Pataday.

April 8, 2011

Watson announced that its subsidiary is seeking approval to market a generic version of a bacterial conjunctivitis treatment.

PARSIPPANY, N.J. — Watson announced that its subsidiary is seeking approval to market a generic version of a bacterial conjunctivitis treatment.

Watson Labs filed an abbreviated new drug application with the Food and Drug Administration for moxifloxacin hydrochloride ophthalmic solution USP in the 0.5% strength. The antibiotic solution is a generic version of Alcon's Vigamox, which had total U.S. sales of about $281 million ended in February, according to IMS Health.

February 17, 2011

Novartis on Thursday morning named Naomi Kelman head of the Novartis OTC division, effective March 2. She will report directly to Joseph Jimenez, Novartis CEO.

BASEL, Switzerland — Novartis on Thursday morning named Naomi Kelman head of the Novartis OTC division, effective March 2. She will report directly to Joseph Jimenez, Novartis CEO.

The Novartis OTC and animal health businesses will become separate Novartis divisions, in addition to the pharmaceuticals, Sandoz (generics), vaccines and diagnostics divisions. As previously announced, following the completion of the merger between Novartis and Alcon, CIBA Vision and Novartis ophthalmic medicines will be merged into the new Alcon eye care division of Novartis.

January 27, 2011

Swiss drug maker Novartis posted sales of $14.2 billion for fourth quarter 2010 and $50.6 billion for the year as a whole, according to an earnings report released Thursday.

BASEL, Switzerland — Swiss drug maker Novartis posted sales of $14.2 billion for fourth quarter 2010 and $50.6 billion for the year as a whole, according to an earnings report released Thursday.

That compared with sales of $12.9 billion and $44.3 billion during fourth quarter 2009 and 2009 as a whole, respectively. Profits for the year were nearly $10 billion, an 18% increase from $8.4 billion in 2009, though profits for the quarter decreased by 2%, from fourth quarter 2009’s $2.32 billion to $2.27 billion in fourth quarter 2010.

December 15, 2010

Novartis on Wednesday announced that its merger agreement with Alcon has been settled to the tune of $12.9 billion. The new $8.7 billion Alcon eye care division, which includes CIBA Vision and selected ophthalmic medicines, will be led by current Alcon president and CEO Kevin Buehler.

BASEL, Switzerland — Novartis on Wednesday announced that its merger agreement with Alcon has been settled to the tune of $12.9 billion. The new $8.7 billion Alcon eye care division, which includes CIBA Vision and selected ophthalmic medicines, will be led by current Alcon president and CEO Kevin Buehler.

Shares of Novartis were up 7.6% to more than $60 in early morning trading.

"The full merger is the logical conclusion of our initial strategic investment in Alcon,” stated Daniel Vasella, Novartis chairman.

October 24, 2010

Kaz, the maker of Vicks, Honeywell and Braun wellness devices, recently launched a new Facebook...

October 11, 2010

Alcon on Monday announced the launch of Systane Balance lubricant eye drops, formulated with HP...

HUENENBERG, Switzerland Alcon on Monday announced the launch of Systane Balance lubricant eye drops, formulated with HP Guar, borate, sorbitol, propylene glycol and Alcon’s exclusive LipiTech System -- an emulsion technology of mineral oil and an anionic phospholipid. The new eye drop is designed to restore the lipid layer and the natural tear film to allow for relief of dry-eye symptoms.

 

October 4, 2010

Eye care company Alcon has appointed a new executive....

HUENENBERG, Switzerland Eye care company Alcon has appointed a new executive.

 

The Swiss drug maker announced Monday the appointment of Robert Karsunky as SVP and CFO, effective Nov. 1. He succeeds Richard Croarkin, who has served as Alcon’s CFO since August 2007.

 

 

September 22, 2010

Eyecare company Alcon has launched a new drug for inflammatory eye conditions....

HUENENBERG, Switzerland Eyecare company Alcon has launched a new drug for inflammatory eye conditions.

 

Alcon announced the launch of TobraDex ST (tobramycin, dexamethasone ophthalmic suspension) in the 0.3%/0.5% strength. The drug is used to treat inflammatory eye conditions treatable with corticosteroids and where bacterial infection or risk of infection exists.

 

 

August 25, 2010

Novartis on Thursday announced that it has completed its purchase of Alcon stock from Nestle,...

BASEL, Switzerland Novartis on Thursday announced that it has completed its purchase of Alcon stock from Nestle, resulting in 77% ownership of Alcon. This has been achieved by completing the acquisition of the remaining 52% of Alcon shares owned by Nestle for a total of $28.3 billion.

 

July 18, 2010

Between lens solutions, eye drops, and related nutritionals and accessories, eye care represents $1 billion...

July 5, 2010

Novartis last week announced that it expects the closing of the transaction for 77% majority...

June 28, 2010

Novartis may need to reconsider its offer to acquire Alcon, according to a press release...

January 19, 2010

Alcon has seen Novartis’ acquisition offer, and it is not impressed....

January 3, 2010

Novartis is looking to purchase the remaining shares in an eye care company....

January 3, 2010

With an eye to the future, Novartis brass envisions a growth arena driven by the...

NEW YORK With an eye to the future, Novartis brass envisions a growth arena driven by the aging Boomer population — eye care, along with all of the products, medicines and surgeries associated with eye care.